Pharos Life Corporation Report issue

For profit Phase 1 Phase 4
Founded: Cambridge ON Canada (2003)
Status: Acquired by Syneron Medical (2010) → now Apax Partners (2017)

Organization Overview

First Clinical Trial
2013
NCT02094703
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Pharos iBio Co., Ltd.

Active Ingredients

Drugs in Phase 4 Trials (2)

levofloxacin (levaquin) (1 trial)

solifenacin (vesicare) (1 trial)

Drugs in Phase 1 Trials (1)

phi-101 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 1)

Communicable Diseases (Phase 4)

Infections (Phase 4)

Ovarian Neoplasms (Phase 1)

Urinary Tract Infections (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 3